P28 glutathione S-transferase - Par Immune
Alternative Names: protein 28 Kd glutathion S transferase - Par Immune; rSh28GST - Par ImmuneLatest Information Update: 15 Mar 2024
At a glance
- Originator Par Immune
- Class Anti-inflammatories; Enzymes; Recombinant proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Crohn's disease
Most Recent Events
- 15 Mar 2024 P28 glutathione S-transferase is available for licensing as of 15 Mar 2024. https://www.linkedin.com/company/par-immune/about/ (Par-Immune LinkedIn Communication, March 2024)
- 24 Dec 2019 Efficacy and adverse events data from the phase II ACROHNEM trial in Crohn's disease released by Par Immune
- 31 Mar 2014 Phase-II clinical trials in Crohn's disease in France (SC) (NCT02281916)